Dimension Therapeutics

Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. Our team comprises biotech industry veterans and thought leaders in gene therapy and rare diseases.

The company is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics.
In conjunction with its launch, Dimension has entered into an exclusive license and collaboration with REGENX Biosciences. REGENX holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its NAV vector technology and related applications. Through its license and collaboration with REGENX, Dimension has acquired preferred access to NAV vector technology and rights within REGENX product programs in multiple rare disease indications. Dimension has completed a Series A financing led by Fidelity Biosciences.

Type
Public
HQ
Cambridge, US
Founded
2013
Size (employees)
81 (est)+2%
Dimension Therapeutics was founded in 2013 and is headquartered in Cambridge, US

Key People at Dimension Therapeutics

Thomas Beck

Thomas Beck

President

Dimension Therapeutics Office Locations

Dimension Therapeutics has an office in Cambridge
Cambridge, US (HQ)
1 Main Street

Dimension Therapeutics Metrics

Dimension Therapeutics Financial Metrics

Revenue (2016)

$11.5 m

Revenue growth (2015-16), %

48%

Net income (2016)

($49 m)

Market capitalization (28-Apr-2017)

$38.8 m

Closing share price (28-Apr-2017)

$1.5

Cash (31-Dec-2016)

$30.2 m
Dimension Therapeutics's current market capitalization is $38.8 m.
Dimension Therapeutics's revenue was reported to be $11.5 m in FY, 2016 which is a 48% increase from the previous period.
FY, 2015FY, 2016

Revenue

$7.8 m$11.5 m

Revenue growth, %

48%

R&D expense

$2.8 m$47.7 m

General and administrative expense

$364 k$12.8 m

Operating expense total

$3.2 m$60.5 m

EBIT

($3.2 m)($49.1 m)

EBIT margin, %

(41%)(428%)

Interest expense

($91 k)$49 k

Interest income

($91 k)$49 k

Net Income

($3.2 m)($49 m)
FY, 2015FY, 2016

Cash

$127 m$30.2 m

Inventories

$4.3 m$1.5 m

Current Assets

$129.9 m$85.3 m

PP&E

$3.3 m$8.4 m

Total Assets

$133.3 m$93.9 m

Accounts Payable

$3.5 m$2.1 m

Total Debt

$1.1 m$4.7 m

Current Liabilities

$13.2 m$20.6 m

Additional Paid-in Capital

$156.8 m$160.2 m

Retained Earnings

($51.2 m)($100.2 m)

Total Equity

$105.6 m$59.9 m

Debt to Equity Ratio

0 x0.1 x

Debt to Assets Ratio

0 x0.1 x

Financial Leverage

1.3 x1.6 x
FY, 2015FY, 2016

Net Income

($3.2 m)($49 m)

Depreciation and Amortization

$1.7 m

Cash From Operating Activities

($192 k)($47.6 m)

Purchases of PP&E

($2.5 m)($6.7 m)

Cash From Investing Activities

($2.5 m)($54.3 m)

Cash From Financing Activities

$4.7 m$5.1 m

Interest Paid

$82 k$136 k

Dimension Therapeutics Market Value History

Dimension Therapeutics Online Presence

Dimension Therapeutics Company Life

You may also be interested in